Mucopolysaccharidosis VII Disease Monitoring Program
study id #: NCT03604835
condition: Mucopolysaccharidosis VII, MPS VII, MPS 7, Sly Syndrome
The objectives of this study are to characterize MPS VII disease presentation and progression and assess long-term effectiveness and safety, including hypersensitivity reactions and immunogenicity of vestronidase alfa.
intervention: No Intervention
last updated: February 26, 2022
start date: January 29, 2018
estimated completion: May 2033
last updated: February 8, 2022
size / enrollment: 35
study description: The Mucopolysaccharidosis VII Disease Monitoring Program (MPS VII DMP) is a global, prospective, multicenter, longitudinal protocol designed to characterize MPS VII disease presentation and progression, assess long-term effectiveness and safety of vestronidase alfa, including hypersensitivity reactions and immunogenicity , as well as prospectively investigate longitudinal change across biomarker(s), clinical assessments, and patient/ caregiver-reported outcome measures in a representative population. The aim of this DMP is to collect data on patients with MPS VII to provide a comprehensive dataset on the clinical presentation, heterogeneity, and disease progression, and meaningful standardized ICH GCP-quality data collected in-clinic across multiple sites globally. The DMP is not a randomized study and both treated and untreated patients will be enrolled.
- Clinical Course of MPS VII Disease
To characterize MPS VII disease presentation and progression over time in patients treated and not treated with vestronidase alfa
- 10 years
Long-term Effectiveness of Vestronidase Alfa
To evaluate longitudinal change in biomarker(s), clinical assessments and patient/caregiver reported outcomes to examine the effectiveness of vestronidase alfa
- 10 years
Long-term Safety of Vestronidase Alfa
Hypersensitivity reactions, immunogenicity and other safety outcomes will be assessed to examine the long-term safety of vestronidase alfa.
- 10 years
• Eligible Sexes: all
Diagnosis of MPS VII based on laboratory diagnosis, including either enzymatic or mutation analysis.
Willing and able to provide written informed consent or, in the case of patients under the age of 18 (or below adult ages as defined by local laws and regulations) or patients >18 years of age who have cognitive deficiencies, provide written assent (if required) and written informed consent by a legally authorized representative after the nature of the DMP has been explained, and prior to any research-related procedures.
Willing to comply with DMP visit schedule.
exclusion criteria: Criteria:
Concurrent participation in other pharmaceutical company-sponsored interventional clinical trial unless approved by Ultragenyx.
Macular Changes in a Mucopolysaccharidosis Type I Patient With Earlier Systemic TherapiesTo describe retinal findings in a patien...
Mucopolysaccharidosis II (MPS II) in a Free-Living Kaka (Nestor Meridionalis) in New ZealandA lysosomal storage disease, identified ...
Deep Intronic Variant in the ARSB Gene as the Genetic Cause for Maroteaux-Lamy Syndrome (MPS VI)Maroteaux-Lamy syndrome (MPS-VI) is a ra...
A Review of the Clinical Outcomes in Idursulfase-Treated and Untreated Filipino Patients With Mucopolysaccharidosis ...Mucopolysaccharidosis type II (MPS II; H...
Awake Airway Endoscopy in Mucopolysaccharidosis: A Case ReportMucopolysaccharidosis (MPS) are a group ...
Heather Lau, MD, MSHeather Lau, M.D. M.S. is a board certif...
Issues of COVID-19-Related Distance Learning for Children With Neuronopathic MucopolysaccharidosesThe COVID-19 pandemic has impacted the e...